Beyond Medical Technologies Inc AI Stock Analysis
Want to see TSE:DOCT full AI Analyst Report?
Beyond Medical Technologies Inc (DOCT) AI Stock Analysis
Beyond Medical Technologies Inc
(CNQX:DOCT)
The company faces an existential financial crisis with collapsed revenue, massive losses, and insolvency. While the stock price has recently risen, technical indicators are flashing extreme overbought warnings, suggesting the rally is unsustainable. The negative P/E ratio confirms the lack of earnings power. The overall score is at the minimum due to the combination of fundamental collapse and extreme technical risk.
Beyond Medical Technologies Inc (DOCT) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 4.76M
- Dividend Yield
- ―
- Average Volume (3M)
- 3,133
- Price to Earnings (P/E)
- -0.6
- Beta (1Y)
- 1.29
- Revenue Growth
- ―
- EPS Growth
- -156.09%
- Country
- Canada
- Employees
- 3
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Industrial - Pollution & Treatment Controls
Beyond Medical Technologies Inc Business Overview & Revenue Model
Company Description
Republic Technologies Inc. provides Ethereum-based technology services. The company develops Validity Network, an attestation platform that provides cryptographically secure and tamper-resistant assurances of data integrity by anchoring data commitme...
Beyond Medical Technologies Inc Financial Statement Overview
Summary
Financial performance is critically poor. Revenue has collapsed to negative territory, net losses exceed $8M, and the company is technically insolvent with negative equity and over $11M in debt. Operating cash flow is deeply negative, indicating an unsustainable burn rate.
Income Statement
1Very NegativeBalance Sheet
1Very NegativeCash Flow
1Very Negative| Breakdown | TTM | Jun 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.48K | 11.48K | 0 | 0 | 0 | 943.42K |
| Gross Profit | 11.48K | 11.48K | 0 | 0 | 0 | -250.00K |
| EBITDA | -1.49M | -2.09M | 0 | -37.96K | -772.91K | -1.26M |
| Net Income | -2.04M | -2.68M | -285 | -596.00K | -1.40M | -2.91M |
Balance Sheet | ||||||
| Total Assets | 15.85M | 15.85M | 13.80K | 95.64K | 608.18K | 1.95M |
| Cash, Cash Equivalents and Short-Term Investments | 2.76M | 2.76M | 13.22K | 64.14K | 536.75K | 1.43M |
| Total Debt | 11.86M | 11.86M | 60.00K | 30.00K | 0 | 85.09K |
| Total Liabilities | 15.71M | 15.71M | 634.46K | 430.35K | 346.94K | 413.28K |
| Stockholders Equity | 133.53K | 133.53K | -620.66K | -334.72K | 261.25K | 1.54M |
Cash Flow | ||||||
| Free Cash Flow | -1.43M | -1.70M | -109.77K | -527.04K | -894.01K | -1.47M |
| Operating Cash Flow | -1.43M | -1.70M | -109.77K | -527.04K | -894.01K | -1.40M |
| Investing Cash Flow | -2.02M | -677.07K | 0 | 0 | 0 | -467.99K |
| Financing Cash Flow | 6.20M | 5.13M | 30.00K | 30.00K | 0 | 2.67M |
Beyond Medical Technologies Inc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOCT, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.17, and below the 200-day MA of 0.16, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 19.61 is Positive, neither overbought nor oversold. The STOCH value of -6.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DOCT.
Beyond Medical Technologies Inc Peers Comparison
Overall Rating
TSE:APL44Neutral
TSE:DOCT37Underperform
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:DOCT | Beyond Medical Technologies Inc | 0.14 | -0.15 | -51.67% | |
| TSE:APL | Appulse Corp | 0.27 | 0.05 | 22.73% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026
